# type 2 diabetes FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/type-2-diabetes

> 10 upcoming FDA catalysts in type 2 diabetes: icovamenib (BMEA) on Q1 2027 (topline data readout); icovamenib (BMEA) on March 2027 (primary completion); LY3457263 (LLY) on May 2027 (primary completion); LY3457263 (LLY) on May to Aug 2027 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for type 2 diabetes?

10 upcoming FDA catalysts in type 2 diabetes: icovamenib (BMEA) on Q1 2027 (topline data readout); icovamenib (BMEA) on March 2027 (primary completion); LY3457263 (LLY) on May 2027 (primary completion); LY3457263 (LLY) on May to Aug 2027 (topline data readout); and 6 more. SEC Form 10-Q: "As of September 30, 2026 icovamenib is now being evaluated across two ongoing Phase II clinical trials (COVALENT-211 and COVALENT-212) in type 2 diabetes, with the primary 26-week HbA1c endpoint readout from our Phase II clinical trial (COVALENT-211) expected in the first quarter of 2027, and the corresponding 26-week primary endpoint HbA1c readout from our Phase II clinical trial (COVALENT-212), expected in the second quarter of 2027." [Calendar and source filings](https://sec-api.dev/indications/type-2-diabetes)

Source: SEC Form 10-Q, accession 0001193125-26-455592, https://www.sec.gov/Archives/edgar/data/1840439/000119312526455592/bmea-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/type-2-diabetes#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 17, 2024 | [Icovamenib topline data readout](https://sec-api.dev/pdufa/icovamenib) | BMEA | type 2 diabetes | completed, positive | "On December 17, 2024, the Company reported positive topline results from its ongoing Phase II COVALENT-111 Study in patients with type 2 diabetes ("T2D")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1840439/000119312524283008/d827448d8k.htm)) |
| May 27, 2025 | [Icosema primary completion](https://sec-api.dev/pdufa/icosema) | NVO | Type 2 Diabetes | completed | "NCT06269107 (A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-27 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06269107)) |
| June 5, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06010004 (A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010004)) |
| August 22, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06045221 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045221)) |
| September 9, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06323161 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323161)) |
| September 15, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06109311 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109311)) |
| September 26, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06192108 (A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06192108)) |
| October 1, 2025 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06323174 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06323174)) |
| Dec 2025 | [Cadisegliatin trial start](https://sec-api.dev/pdufa/cadisegliatin) | VTVT | type 2 diabetes | completed | "In December 2025, together with our partner G42 Investments AI Holding RSC Ltd. ("G42 Investments"), we initiated a double-blind, randomized, controlled Phase 2 trial in the Middle East region in people with type 2 diabetes ("T2D")." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/vtvt-20251231.htm)) |
| March 4, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06221969 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06221969)) |
| March 27, 2026 | [Awiqli (awiqli) FDA approval](https://sec-api.dev/pdufa/awiqli) | NVO | type 2 diabetes | completed, approved | "Bagsv&aelig;rd, Denmark, 27 March 2026 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326001959/f6k_032626.htm)) |
| Q2 2026 | [UBT251 trial start](https://sec-api.dev/pdufa/ubt251) | NVO | type 2 diabetes | scheduled | "•Novo Nordisk expects to initiate the global phase 2 trial with UBT251 in people with type 2 diabetes in the second quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000035327826000018/caq12026.htm)) |
| June 29, 2026 | [Oral semaglutide primary completion](https://sec-api.dev/pdufa/oral-semaglutide) | NVO | Type 2 Diabetes | completed | "NCT07271251 (A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07271251)) |
| June 30, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06010004 (A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010004?tab=results)) |
| September 15, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06045221 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045221?tab=results)) |
| October 1, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06109311 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109311?tab=results)) |
| October 16, 2026 | [Foundayo (orforglipron calcium) topline data readout](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06192108 (A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-26 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-10-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06192108?tab=results)) |
| October 26, 2026 | [Retatrutide primary completion](https://sec-api.dev/pdufa/retatrutide) | LLY | Type 2 Diabetes | completed | "NCT06297603 (Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297603)) |
| Oct 2026 to Jan 2027 | [Retatrutide topline data readout](https://sec-api.dev/pdufa/retatrutide) | LLY | Type 2 Diabetes | scheduled | "NCT06297603 (Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06297603)) |
| Q1 2027 | [Icovamenib topline data readout](https://sec-api.dev/pdufa/icovamenib) | BMEA | Type 2 Diabetes | scheduled | "As of September 30, 2026 icovamenib is now being evaluated across two ongoing Phase II clinical trials (COVALENT-211 and COVALENT-212) in type 2 diabetes, with the primary 26-week HbA1c endpoint readout from our Phase II clinical trial (COVALENT-211) expected in the first quarter of 2027, and the corresponding 26-week primary endpoint HbA1c readout from our Phase II clinical trial (COVALENT-212), expected in the second quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1840439/000119312526455592/bmea-20260930.htm)) |
| March 2027 | [Icovamenib primary completion](https://sec-api.dev/pdufa/icovamenib) | BMEA | Type 2 Diabetes | scheduled | "NCT07502495 (Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Biomea Fusion Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07502495)) |
| May 2027 | [LY3457263 primary completion](https://sec-api.dev/pdufa/ly3457263) | LLY | Type 2 Diabetes | scheduled | "NCT06897475 (A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897475)) |
| May to Aug 2027 | [LY3457263 topline data readout](https://sec-api.dev/pdufa/ly3457263) | LLY | Type 2 Diabetes | scheduled | "NCT06897475 (A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897475)) |
| June 2027 | [Icovamenib primary completion](https://sec-api.dev/pdufa/icovamenib) | BMEA | Type 2 Diabetes | scheduled | "NCT07502508 (Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Biomea Fusion Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07502508)) |
| Jun to Sep 2027 | [Icovamenib topline data readout](https://sec-api.dev/pdufa/icovamenib) | BMEA | Type 2 Diabetes | scheduled | "NCT07502508 (Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Biomea Fusion Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07502508)) |
| December 2027 | [Trulicity (dulaglutide) primary completion](https://sec-api.dev/pdufa/dulaglutide) | LLY | Type 2 Diabetes | scheduled | "NCT06739122 (A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06739122)) |
| Dec 2027 to Mar 2028 | [Trulicity (dulaglutide) topline data readout](https://sec-api.dev/pdufa/dulaglutide) | LLY | Type 2 Diabetes | scheduled | "NCT06739122 (A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06739122)) |
| Jul to Oct 2028 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | scheduled | "NCT07931573 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931573)) |
| July 2028 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | scheduled | "NCT07931573 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07931573)) |

## Drugs

- [Icovamenib](https://sec-api.dev/pdufa/icovamenib) (BMEA)
- [Icosema](https://sec-api.dev/pdufa/icosema) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [Cadisegliatin](https://sec-api.dev/pdufa/cadisegliatin) (VTVT)
- [Awiqli (awiqli)](https://sec-api.dev/pdufa/awiqli) (NVO)
- [UBT251](https://sec-api.dev/pdufa/ubt251) (NVO)
- [Oral semaglutide](https://sec-api.dev/pdufa/oral-semaglutide) (NVO)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [LY3457263](https://sec-api.dev/pdufa/ly3457263) (LLY)
- [Trulicity (dulaglutide)](https://sec-api.dev/pdufa/dulaglutide) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/type-2-diabetes.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "type 2 diabetes FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/type-2-diabetes

```bibtex
@misc{secapidev_indications_type_2_diabetes_20261116,
  title        = {type 2 diabetes FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/type-2-diabetes}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_type_2_diabetes_20261116","title":"type 2 diabetes FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/type-2-diabetes","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
